Triple combination therapy, such as anti-PD-L1 antibody, poly-(ADP-ribose) polymerase inhibitor, and MEK inhibitor, was also applied to overcome resistance to anti-PD-L1 therapies in KRAS mutant cancer (22). The gene discussed is MAP2K7; the disease is cancer.